Virios Therapeutics Stock Moves Higher On Promising IMC-1 Safety Data In Mid-Stage Fibromyalgia Trial

Virios Therapeutics Inc VIRI has announced that data from its Phase 2a PRID-201 trial demonstrated that IMC-1 was better tolerated than placebo in patients with fibromyalgia.
The disease is characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory, and mood issues.
The results were highlighted in a poster presentation at the International Association for the Study of Pain (IASP) World Congress.
IMC‑1 exhibited an encouraging safety profile, as adverse events occurred at a lower rate and were less severe in the IMC‑1 treatment group compared with placebo.
The discontinuation rate was nearly 3‑fold higher in patients receiving placebo than the IMC‑1 group, suggesting that treatment with IMC‑1 was unusually well‑tolerated.
Significant reductions in pain, fatigue, and other vital symptoms were observed.
Price Action: VIRI shares are up 12.1% at $6.30 during the premarket session on the last check Wednesday.